Kestra Medical Technologies

Kestra Medical Technologies is a private medical device company commercializing the ASSURE® Cardiac Recovery System, a modern wearable cardioverter defibrillator (WCD) integrated with a digital health platform. Founded in 2014 and headquartered in Kirkland, Washington, the company targets the significant market of heart failure patients with low ejection fraction who are at elevated risk of sudden cardiac arrest during a vulnerable recovery period. Kestra differentiates its platform through a patient-centric design philosophy, remote patient data management via the Kestra CareStation™, and real-world clinical evidence from studies like the ACE-PAS trial. The company operates in the competitive cardiac rhythm management space but leverages connectivity and data to improve patient compliance and clinical oversight.

The ASSURE® Cardiac Recovery System integrates a Wearable Cardioverter Defibrillator (WCD) for continuous monitoring and therapeutic defibrillation, a patient mobile app for engagement and data transmission, and the Kestra CareStation™ cloud-based remote patient data platform for clinician monitoring and management. The platform utilizes integrated sensing, autonomous arrhythmia detection, and mobile connectivity.

The wearable defibrillator market is dominated by ZOLL Medical Corporation (a subsidiary of Asahi Kasei) and its LifeVest® product. Kestra's ASSURE system is the primary competitor, differentiating on its modern, connected system design, patient-centric "Empathy Powered Design," and integrated remote monitoring platform. Competition is based on clinical data, patient comfort/compliance, features, and reimbursement.